Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hemostasis disorders after transfusions].

G Weissbach, M Domula, H Lenk

    Folia Haematologica (Leipzig, Germany : 1928)
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Haemophilia treatment centres in Germany].

    Hamostaseologie·2012
    Same author

    Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.

    Transplantation proceedings·2009
    Same author

    Cat eye syndrome associated with schizophrenia.

    Pharmacopsychiatry·2007
    Same author

    Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.

    Haemophilia : the official journal of the World Federation of Hemophilia·2007
    Same author

    Acute portal vein thrombosis after splenic embolization and splenectomy for autoimmune pancytopenia.

    European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie·2005
    Same author

    Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.

    Annals of the New York Academy of Sciences·2005

    Blood transfusions can cause bleeding issues, particularly in patients with existing haemostasis defects or during massive transfusions. Intensive therapy for haemophilia A may lead to paradoxical bleeding due to platelet dysfunction, but plasmapheresis can help manage thrombocytopenias.

    Area of Science:

    • Transfusion Medicine
    • Haemostasis and Thrombosis
    • Immunohaematology

    Context:

    • Transfusion of blood and blood products can lead to immunological and non-immunological disturbances of haemostasis.
    • Massive transfusions, particularly with stored blood, can induce complex coagulation defects.
    • Patients with haemophilia A undergoing intensive substitution therapy may experience paradoxical bleeding despite high factor VIII levels.

    Purpose:

    • To investigate the mechanisms and management of transfusion-related haemostatic disturbances.
    • To explore the causes of paradoxical bleeding in haemophilia A and potential therapeutic interventions.
    • To analyze the development and management of factor-specific inhibitors in haemophilic patients.

    Summary:

    • Transfusion-associated haemostatic abnormalities can occur, influenced by pre-existing conditions and transfusion volume.

    Related Experiment Videos

  • Paradoxical bleeding in haemophilia A is linked to thrombocyte dysfunction, potentially caused by fibrin(ogen) derivatives, and may respond to plasmapheresis.
  • Factor-specific inhibitors in haemophilia A can elicit an anamnestic response, manageable with immunosuppressants like cyclophosphamide or bypassing agents, with potential for complete inhibitor elimination through high-dose factor VIII concentrate therapy.

    • Impact:

    • Understanding these complications is crucial for optimizing transfusion strategies and patient safety.
    • Effective management of paradoxical bleeding and inhibitor development can improve treatment outcomes for haemophilia patients.
    • This research contributes to the development of safer and more effective transfusion protocols and haemophilia therapies.